AMGEN WINS EPO PATENT FIGHT IN FEDERAL APPEALS COURT; GENETICS INSTITUTE BARRED FROM U.S. MARKET BECAUSE ITS PROCESS DID NOT PRODUCE CLAIMED MATERIAL